To identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication
Signia Therapeutics initial strategy focuses on the identification and repurposing of already FDA-approved drugs for new antiviral indication. The Company’s proposes a novel strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication against one or several human respiratory viruses that could be evaluated in clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Signia Therapeutics innovative approach will offer intrinsic de-risking of drug discovery process:
- Significant cost and time reduction to validate clinical trial drug candidates
- Enable rapid transition to phase 2 clinical trials
- Significant shortening of response times of widespread outbreaks
- New value added IP opportunities
- Rapid return on investment for drug development to market of new antivirals
Several competitive advantages
The novel drug-discovery strategy proposed by Signia Therapeutics presents three obvious advantages:
- By targeting host cellular pathways instead of viral proteins, the Company should achieve broad-spectrum antiviral efficacy and minimize the risk of emergence of drug-resistant viruses, which is a serious problem with current antivirals against error-prone RNA viruses.
- Signia’s versatile platform can further be expanded for the identification of active molecules against other classes of viruses as well as intracellular bacteria or parasites.
- Since the Company aims at identifying new indications for existing drugs, this is a more rapid and cost-effective drug development alternative, with important implications for rapid response outbreak preparedness.